home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

35.78 +0.83 (+2.37%)

Official Closing Price Updated: 4:15 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

March 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

March 03, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Why Corcept (CORT) Shares Are Sliding Today

February 27, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.3% in the pre-market session after the company reported weak fourth quarter results: its revenue missed significantly, and its EPS...

Via StockStory

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Exploring NASDAQ:CORT's high growth characteristics. ↗

January 15, 2025

Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) suited for high growth investing?

Via Chartmill

Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. ↗

January 15, 2025

CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout.

Via Chartmill

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

January 10, 2025

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.

Via Chartmill

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

February 26, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

February 26, 2025

From Corcept Therapeutics

Via Business Wire

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗

February 26, 2025

CORCEPT THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:CORT is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Via Chartmill

Corcept (CORT) Q4 Earnings Report Preview: What To Look For

February 25, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT). ↗

December 12, 2024

Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).

Via Chartmill

NASDAQ:CORT, a strong growth stock, setting up for a breakout. ↗

December 12, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.

Via Chartmill

In the world of growth stocks, NASDAQ:CORT shines as a value proposition. ↗

November 04, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:CORT.

Via Chartmill

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

February 12, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Looking for growth without the hefty price tag? Consider NASDAQ:CORT. ↗

January 31, 2025

CORCEPT THERAPEUTICS INC could be undervalued. NASDAQ:CORT is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.

Via Chartmill

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

December 30, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Earnings Preview: Corcept Therapeutics ↗

October 29, 2024

Via Benzinga

Key Takeaways From Corcept Therapeutics Analyst Ratings ↗

October 18, 2024

Via Benzinga

Investors should take note of NASDAQ:CORT, a growth stock that remains attractively priced. ↗

December 20, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) stands out as a growth opportunity that won't break the bank.

Via Chartmill

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

December 16, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes ↗

December 13, 2024

Corcept Therapeutics reports positive Phase 4 CATALYST results, showing Korlym significantly improves hemoglobin A1c in hypercortisolism patients.

Via Benzinga

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

December 12, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

December 11, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗

December 11, 2024

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Via Investor's Business Daily

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. ↗

November 28, 2024

NASDAQ:CORT is showing decent growth, but is still valued reasonably.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 30, 2024

Via Benzinga

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

October 30, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 23, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com